Immunohistochemical Evaluation of CON6D/B5
Authors:
- Sean K. LauSLSean K. Lau
- Premi ThomasPTPremi Thomas
- Lawrence M. WeissLWLawrence M. Weiss
- 1 May 2010
- journal article
- research article
- Published by Wolters Kluwer Health in Applied Immunohistochemistry & Molecular Morphology
- Vol. 18 (3) , 273-277
Abstract
Immunohistochemical evaluation of CD30 expression is commonly performed in the assessment of hematopoietic disorders and germ cell tumors. A new monoclonal antibody, CON6D/B5, directed against the CD30 antigen has become commercially available for use in formalin-fixed paraffin-embedded tissue samples. The performance characteristics of CON6D/B5 were tested and compared with the well-characterized monoclonal CD30 antibody Ber-H2. Among the various neoplasms analyzed, there was complete concordance between the results of CON6D/B5 and Ber-H2 staining. Similar to Ber-H2, CON6D/B5 immunoreactivity was observed in all cases of classical Hodgkin lymphoma, anaplastic large cell lymphoma, and embryonal carcinoma, with no staining detectable in any of the other various tumors evaluated, including several neoplasms earlier reported as showing CD30 positivity by other investigators. The labeling intensity was much stronger with CON6D/B5 compared with Ber-H2, although no significant differences were observed with regard to the numbers of positively labeled cells in individual cases. The monoclonal antibody CON6D/B5 offers a suitable alternative to Ber-H2 for the immunohistochemical detection of CD30 expression.Keywords
This publication has 15 references indexed in Scilit:
- Expression of CD30 (Ber‐H2) in nasopharyngeal carcinoma, undifferentiated type and lymphoepithelioma‐like carcinoma. A comparison study with anaplastic large cell lymphomaHistopathology, 2006
- Expression of the CD30 antigen in non-lymphoid tissues and cellsThe Journal of Pathology, 2000
- CD30 in Normal and Neoplastic CellsClinical Immunology, 1999
- CD30: expression and function in health and diseaseSeminars in Immunology, 1998
- A comparative evaluation of immunohistochemical markers for the differential diagnosis of malignant pleural tumoursHistopathology, 1998
- CD30 (Ber-H2) Expression in Nonhematopoietic TumorsApplied Immunohistochemistry & Molecular Morphology, 1998
- CD30 expression in seminomaHuman Pathology, 1996
- Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's diseaseCell, 1992
- Expression of Ki-1 antigen (CD30) in mesenchymal tumorsCancer, 1990
- Production of a monoclonal antibody specific for Hodgkin and Sternberg–Reed cells of Hodgkin's disease and a subset of normal lymphoid cellsNature, 1982